{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,14]],"date-time":"2026-03-14T02:30:48Z","timestamp":1773455448371,"version":"3.50.1"},"reference-count":31,"publisher":"Public Library of Science (PLoS)","issue":"9","license":[{"start":{"date-parts":[[2022,9,2]],"date-time":"2022-09-02T00:00:00Z","timestamp":1662076800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100003243","name":"Ministerstvo Zdravotnictv\u00ed Cesk\u00e9 Republiky","doi-asserted-by":"publisher","award":["00064203"],"award-info":[{"award-number":["00064203"]}],"id":[{"id":"10.13039\/501100003243","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"abstract":"<jats:sec id=\"sec001\">\n<jats:title>Background and aims<\/jats:title>\n<jats:p>SARS-CoV-2 is a worldwide serious health problem and vaccination seems to have a crucial role in managing the COVID-19 pandemic. The aim of this prospective observational study was to monitor the trend of antibodies against SARS-CoV-2 after vaccination with BNT162b2 (COMIRNATY) in patients with inflammatory bowel disease treated by immunosuppressive and\/or biological therapy, demonstrate whether any type of this therapy is associated with poorer production of antibodies against COVID-19 and evaluate the safety of vaccination against COVID-19 in these patients.<\/jats:p>\n<\/jats:sec>\n<jats:sec id=\"sec002\">\n<jats:title>Methods<\/jats:title>\n<jats:p>Eighty-seven eligible patients from one tertiary gastroenterological center with inflammatory bowel disease (60 with CD, 27 with UC) treated by immunosuppressive and\/or biological therapy from the antiTNF\u03b1 group were indicated to vaccination against SARS-CoV-2. Effectiveness of vaccination was evaluated by the values of antibodies before and 4 weeks after 2<jats:sup>nd<\/jats:sup> dose of vaccine. Additional goal was to evaluate adverse events of vaccination.<\/jats:p>\n<\/jats:sec>\n<jats:sec id=\"sec003\">\n<jats:title>Results<\/jats:title>\n<jats:p>Before the 2<jats:sup>nd<\/jats:sup> dose of vaccine, geometric mean of SARS-CoV-2 IgG antibodies were 40.7 U\/ml in the biological therapy group, 34.8 U\/ml in the azathioprine group and 44.8 U\/ml in the combination therapy group of patients. The geometric means were 676.5.7 U\/ml in the biological therapy group, 614.4 U\/ml in the azathioprine group and 500.1 U\/ml in the combination therapy group of patients four weeks after 2<jats:sup>nd<\/jats:sup> dose. Statistically significant differences between these groups were not proved. Several non-severe local and general adverse events were present in our patients with a majority of these events on the day of vaccine administration and the day after, no anaphylactic reactions were present.<\/jats:p>\n<\/jats:sec>\n<jats:sec id=\"sec004\">\n<jats:title>Conclusions<\/jats:title>\n<jats:p>Our measurements proved the efficacy and safety of vaccination against SARS-CoV-2 in patients with inflammatory bowel disease treated by immunosuppressive and\/or biological therapy. Statistically significant differences between our groups of patients were not proved.<\/jats:p>\n<\/jats:sec>","DOI":"10.1371\/journal.pone.0273612","type":"journal-article","created":{"date-parts":[[2022,9,2]],"date-time":"2022-09-02T17:33:09Z","timestamp":1662139989000},"page":"e0273612","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":5,"title":["Efficacy and safety of SARS-CoV-2 vaccination in patients with inflammatory bowel disease on immunosuppressive and biological therapy: Prospective observational study"],"prefix":"10.1371","volume":"17","author":[{"given":"Martin","family":"Wasserbauer","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8004-844X","authenticated-orcid":true,"given":"Stepan","family":"Hlava","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Milan","family":"Trojanek","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jan","family":"Stovicek","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2105-3462","authenticated-orcid":true,"given":"Tomas","family":"Milota","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jiri","family":"Drabek","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Petra","family":"Koptov\u00e1","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrea","family":"Cupkova","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dita","family":"Pichlerov\u00e1","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Barbora","family":"Kucerova","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stepan","family":"Coufal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Radan","family":"Keil","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"340","published-online":{"date-parts":[[2022,9,2]]},"reference":[{"issue":"1","key":"pone.0273612.ref001","doi-asserted-by":"crossref","first-page":"69","DOI":"10.7326\/M20-5008","article-title":"Transmission of SARS-CoV-2: A Review of Viral, Host, and Environmental Factors","volume":"174","author":"EA Meyerowitz","year":"2021","journal-title":"Ann Intern Med"},{"issue":"9","key":"pone.0273612.ref002","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1056\/NEJMc2001272","article-title":"Importation and Human-to-Human Transmission of a Novel Coronavirus in Vietnam","volume":"382","author":"LT Phan","year":"2020","journal-title":"N Engl J Med"},{"issue":"2","key":"pone.0273612.ref003","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1016\/j.jpha.2020.03.001","article-title":"Molecular immune pathogenesis and diagnosis of COVID-19","volume":"10","author":"X Li","year":"2020","journal-title":"J Pharm Anal"},{"issue":"5","key":"pone.0273612.ref004","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1016\/S2213-2600(20)30079-5","article-title":"Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study","volume":"8","author":"X Yang","year":"2020","journal-title":"Lancet Respir Med"},{"key":"pone.0273612.ref005","first-page":"1868","volume-title":"Sleisenger and Fordtran\u2019s gastrointestinal and liver disease: pathophysiology, diagnosis, management","author":"M Feldman","year":"2021","edition":"11"},{"key":"pone.0273612.ref006","first-page":"3","volume-title":"Crohn\u2019s disease and ulcerative colitis from epidemiology and immunobiology to a rational diagnostic and therapeutic approach","author":"D. Baumgart","year":"2012","edition":"1"},{"key":"pone.0273612.ref007","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1038\/nature11582","article-title":"Host-microbe interactions have shaped the genetic architecture of inflammatory bowel disease","volume":"491","author":"L Jostins","year":"2012","journal-title":"Nature"},{"issue":"6","key":"pone.0273612.ref008","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1016\/j.crohns.2013.12.013","article-title":"Second European evidence-based consensus on the prevention, diagnosis and management of opportunistic infections in inflammatory bowel disease","volume":"8","author":"JF Rahier","year":"2014","journal-title":"J Crohns Colitis"},{"issue":"11","key":"pone.0273612.ref009","doi-asserted-by":"crossref","first-page":"1222","DOI":"10.1016\/j.dld.2020.09.002","article-title":"COVID-19 in patients with inflammatory bowel disease: A systematic review of clinical data","volume":"52","author":"FS Macaluso","year":"2020","journal-title":"Dig Liver Dis"},{"issue":"3","key":"pone.0273612.ref010","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/j.dld.2020.12.013","article-title":"Risk of COVID 19 in patients with inflammatory bowel diseases compared to a control population","volume":"53","author":"G Maconi","year":"2021","journal-title":"Dig Liver Dis"},{"issue":"2","key":"pone.0273612.ref011","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1053\/j.gastro.2020.05.032","article-title":"Corticosteroids, But Not TNF Antagonists, Are Associated With Adverse COVID-19 Outcomes in Patients With Inflammatory Bowel Diseases: Results From an International Registry","volume":"159","author":"EJ Brenner","year":"2020","journal-title":"Gastroenterology"},{"issue":"7830","key":"pone.0273612.ref012","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1038\/s41586-020-2798-3","article-title":"SARS-CoV-2 vaccines in development","volume":"586","author":"F. Krammer","year":"2020","journal-title":"Nature"},{"issue":"12","key":"pone.0273612.ref013","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1080\/14787210.2020.1797487","article-title":"Resolution of coronavirus disease 2019 (COVID-19)","volume":"18","author":"K Habas","journal-title":"Expert Rev Anti Infect Ther"},{"issue":"6","key":"pone.0273612.ref014","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1016\/S1473-3099(20)30243-7","article-title":"Estimates of the severity of coronavirus disease 2019: a model-based analysis","volume":"20","author":"R Verity","year":"2020","journal-title":"Lancet Infect Dis"},{"issue":"20","key":"pone.0273612.ref015","doi-asserted-by":"crossref","first-page":"2052","DOI":"10.1001\/jama.2020.6775","article-title":"Presenting Characteristics, Comorbidities, and Outcomes Among 5700 Patients Hospitalized With COVID-19 in the New York City Area","volume":"323","author":"S Richardson","year":"2020","journal-title":"JAMA"},{"issue":"7821","key":"pone.0273612.ref016","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1038\/s41586-020-2521-4","article-title":"Factors associated with COVID-19-related death using OpenSAFELY","volume":"584","author":"EJ Williamson","year":"2020","journal-title":"Nature"},{"key":"pone.0273612.ref017","doi-asserted-by":"crossref","first-page":"m1966","DOI":"10.1136\/bmj.m1966","article-title":"Factors associated with hospital admission and critical illness among 5279 people with coronavirus disease 2019 in New York City: prospective cohort study","volume":"369","author":"CM Petrilli","year":"2020","journal-title":"BMJ"},{"issue":"9","key":"pone.0273612.ref018","doi-asserted-by":"crossref","first-page":"e1003321","DOI":"10.1371\/journal.pmed.1003321","article-title":"Comorbidities associated with mortality in 31,461 adults with COVID-19 in the United States: A federated electronic medical record analysis","volume":"17","author":"SL Harrison","year":"2020","journal-title":"PLoS Med"},{"issue":"1","key":"pone.0273612.ref019","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1053\/j.gastro.2020.04.012","article-title":"AGA Clinical Practice Update on Management of Inflammatory Bowel Disease During the COVID-19 Pandemic: Expert Commentary","volume":"159","author":"DT Rubin","year":"2020","journal-title":"Gastroenterology"},{"issue":"4","key":"pone.0273612.ref020","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1136\/gutjnl-2020-322539","article-title":"Effect of IBD medications on COVID-19 outcomes: results from an international registry","volume":"70","author":"RC Ungaro","year":"2021","journal-title":"Gut"},{"issue":"9","key":"pone.0273612.ref021","doi-asserted-by":"crossref","first-page":"1336","DOI":"10.7326\/M21-1341","article-title":"Safety and Immunogenicity of Anti-SARS-CoV-2 Messenger RNA Vaccines in Recipients of Solid Organ Transplants","volume":"174","author":"O Marion","year":"2021","journal-title":"Ann Intern Med"},{"issue":"21","key":"pone.0273612.ref022","doi-asserted-by":"crossref","first-page":"2204","DOI":"10.1001\/jama.2021.7489","article-title":"Antibody Response to 2-Dose SARS-CoV-2 mRNA Vaccine Series in Solid Organ Transplant Recipients","volume":"325","author":"BJ Boyarsky","year":"2021","journal-title":"JAMA"},{"issue":"3","key":"pone.0273612.ref023","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1016\/S2468-1253(21)00024-8","article-title":"SARS-CoV-2 vaccination for patients with inflammatory bowel disease: a British Society of Gastroenterology Inflammatory Bowel Disease section and IBD Clinical Research Group position statement","volume":"6","author":"JL Alexander","year":"2021","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"4","key":"pone.0273612.ref024","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1136\/gutjnl-2020-324000","article-title":"SARS-CoV-2 vaccination for patients with inflammatory bowel diseases: recommendations from an international consensus meeting","volume":"70","author":"CA Siegel","year":"2021","journal-title":"Gut"},{"issue":"4","key":"pone.0273612.ref025","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1002\/ygh2.473","article-title":"SARS-CoV-2 vaccination in patients with inflammatory bowel disease","volume":"3","author":"RE Prentice","year":"2021","journal-title":"GastroHep"},{"issue":"27","key":"pone.0273612.ref026","doi-asserted-by":"crossref","first-page":"2603","DOI":"10.1056\/NEJMoa2034577","article-title":"Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine","volume":"383","author":"FP Polack","year":"2020","journal-title":"N Engl J Med"},{"issue":"10287","key":"pone.0273612.ref027","doi-asserted-by":"crossref","first-page":"1819","DOI":"10.1016\/S0140-6736(21)00947-8","article-title":"Impact and effectiveness of mRNA BNT162b2 vaccine against SARS-CoV-2 infections and COVID-19 cases, hospitalisations, and deaths following a nationwide vaccination campaign in Israel: an observational study using national surveillance data","volume":"397","author":"EJ Haas","year":"2021","journal-title":"Lancet"},{"issue":"10286","key":"pone.0273612.ref028","doi-asserted-by":"crossref","first-page":"1725","DOI":"10.1016\/S0140-6736(21)00790-X","article-title":"COVID-19 vaccine coverage in health-care workers in England and effectiveness of BNT162b2 mRNA vaccine against infection (SIREN): a prospective, multicentre, cohort study","volume":"397","author":"VJ Hall","year":"2021","journal-title":"Lancet"},{"issue":"18","key":"pone.0273612.ref029","doi-asserted-by":"crossref","first-page":"1775","DOI":"10.1056\/NEJMc2101951","article-title":"BNT162b2 mRNA Covid-19 Vaccine Effectiveness among Health Care Workers","volume":"384","author":"S Benenson","year":"2021","journal-title":"N Engl J Med"},{"issue":"10","key":"pone.0273612.ref030","doi-asserted-by":"crossref","first-page":"1884","DOI":"10.1136\/gutjnl-2021-324789","article-title":"Infliximab is associated with attenuated immunogenicity to BNT162b2 and ChAdOx1 nCoV-19 SARS-CoV-2 vaccines in patients with IBD","volume":"70","author":"NA Kennedy","year":"2021","journal-title":"Gut"},{"issue":"8","key":"pone.0273612.ref031","doi-asserted-by":"crossref","first-page":"283","DOI":"10.15585\/mmwr.mm7008e3","article-title":"First Month of COVID-19 Vaccine Safety Monitoring\u2014United States, December 14, 2020-January 13, 2021","volume":"70","author":"J Gee","year":"2021","journal-title":"MMWR Morb Mortal Wkly Rep"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0273612","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,9,2]],"date-time":"2022-09-02T17:33:34Z","timestamp":1662140014000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0273612"}},"subtitle":[],"editor":[{"given":"Hsu-Heng","family":"Yen","sequence":"first","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2022,9,2]]},"references-count":31,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2022,9,2]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0273612","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,9,2]]}}}